Nexteer's Global First Steer-by-Wire Goes into Production

Nexteer's Global First Steer-by-Wire Goes into Production

BEIJING, April 26, 2026 /PRNewswire/ -- Nexteer Automotive helped a leading Chinese new energy vehicle (NEV) manufacturer bring the world's first production passenger vehicle with a full drive‑by‑wire chassis to market. The vehicle features...

Strong results achieved in world-first Graphene enhanced cement roof tile trial

Strong results achieved in world-first Graphene enhanced cement roof tile trial

Highlights Production trial of graphene enhanced roof tiles with FP McCann achieves CO2 reduction of up to 14% Project conducted in the United Kingdom also showed 26% reduction in CEM I-to-concrete ratio required to produce concrete roof tiles...

Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone

Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone

GOTHENBURG, Sweden, April 21, 2026 /PRNewswire/ -- "We succeeded in surpassing last year's record-breaking first quarter with organic growth in both net sales and order intake," says Mattias Perjos, President & CEO at Getinge. The medtech...

Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles

Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles

HONG KONG, April 1, 2026 /PRNewswire/ -- On 31 March, Fosun International held its 2025 annual results presentation in Shanghai. Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of...

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas

HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent...

CNOOC Limited Hits New Records of Reserves and Production in 2025, Profit Resilience Continues to Consolidate

CNOOC Limited Hits New Records of Reserves and Production in 2025, Profit Resilience Continues to Consolidate

HONG KONG, March 26, 2026 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announced its 2025 annual results for the year ended December 31, 2025. Net production was approximately...

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase...

OCI Global Reports H2 2025 and FY 2025 Unaudited Results

OCI Global Reports H2 2025 and FY 2025 Unaudited Results

AMSTERDAM, March 16, 2026 /PRNewswire/ -- Foreword Subsequent to the reporting period, geopolitical developments in the Middle East have led to an immediate and significant increase in European natural gas prices of approximately 60%, resulting in...

OPTRUST FULLY FUNDED FOR 17(TH) CONSECUTIVE YEAR

OPTRUST FULLY FUNDED FOR 17(TH) CONSECUTIVE YEAR

TORONTO, March 11, 2026 /PRNewswire/ -- Today, OPTrust released its 2025 Funded Status Report — Service & Security – Since 1995 — which details the Plan's financial results and funded status, while marking its 30th anniversary. In 2025, OPTrust...

Registrational Phase III AMPLIFY trial: Target number of participants achieved

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 27
  • menu
    menu